BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $919 | -30.0% | 13,500 | -16.0% | 0.01% | -22.2% |
| Q2 2023 | $1,312 | +36.4% | 16,067 | +23.9% | 0.01% | +28.6% |
| Q1 2023 | $962 | +5.4% | 12,971 | +17.8% | 0.01% | 0.0% |
| Q4 2022 | $913 | -99.9% | 11,011 | +225.4% | 0.01% | -12.5% |
| Q3 2022 | $961,000 | -17.2% | 3,384 | +1.1% | 0.01% | -11.1% |
| Q2 2022 | $1,160,000 | +14.2% | 3,346 | +42.6% | 0.01% | +50.0% |
| Q1 2022 | $1,016,000 | -36.8% | 2,347 | -24.5% | 0.01% | -33.3% |
| Q4 2021 | $1,608,000 | +11.5% | 3,109 | +4.5% | 0.01% | 0.0% |
| Q3 2021 | $1,442,000 | +67.9% | 2,975 | +56.0% | 0.01% | +50.0% |
| Q2 2021 | $859,000 | +1490.7% | 1,907 | +770.8% | 0.01% | – |
| Q3 2020 | $54,000 | +31.7% | 219 | +1.9% | 0.00% | -100.0% |
| Q2 2020 | $41,000 | 0.0% | 215 | 0.0% | 0.00% | – |
| Q1 2020 | $41,000 | -12.8% | 215 | 0.0% | 0.00% | – |
| Q4 2019 | $47,000 | 0.0% | 215 | -10.4% | 0.00% | – |
| Q3 2019 | $47,000 | -6.0% | 240 | 0.0% | 0.00% | – |
| Q2 2019 | $50,000 | +4.2% | 240 | 0.0% | 0.00% | – |
| Q1 2019 | $48,000 | +60.0% | 240 | +15.9% | 0.00% | – |
| Q4 2018 | $30,000 | -28.6% | 207 | 0.0% | 0.00% | – |
| Q3 2018 | $42,000 | +35.5% | 207 | 0.0% | 0.00% | – |
| Q2 2018 | $31,000 | 0.0% | 207 | 0.0% | 0.00% | – |
| Q1 2018 | $31,000 | – | 207 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |